Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	17.38	8.55	-4.94	-16.54	-27.13
Depreciation & Amortization	0.79	0.81	1.03	1.06	1.12
Stock-Based Compensation	6.07	3.66	4.75	5.74	6.2
Other Adjustments	-0.49	-4.05	1.71	0.97	0.67
Change in Receivables	-0.76	-1.28	2.26	-3.32	-2.58
Changes in Inventories	-11.64	5.33	0.15	-1.08	-1.92
Changes in Accounts Payable	2.27	-1.07	0.55	-0.74	0.98
Changes in Accrued Expenses	1.84	1.21	2.16	0.86	0.35
Changes in Unearned Revenue	0.1	-0.73	-0.64	-0.39	-0.1
Changes in Other Operating Activities	-0.11	-0.33	0.09	-1.64	-1.75
Operating Cash Flow	13.5	12.11	7.12	-15.1	-24.16
Operating Cash Flow Growth	11.52%	70.14%	-	-	-
Capital Expenditures	-0.29	-0.16	-0.15	-0.33	-0.41
Sale of Property, Plant & Equipment	-	0.02	0.01	-	-
Investing Cash Flow	-0.29	-0.14	-0.14	-0.33	-0.41
Issuance of Common Stock	7.25	5.43	-	7.75	36.24
Repurchase of Common Stock	-0.25	-	-	-	-
Net Common Stock Issued (Repurchased)	7	5.43	-	7.75	36.24
Other Financing Activities	-0.08	-0.06	-0.09	-0.09	-0.14
Financing Cash Flow	6.92	5.37	-0.09	7.65	36.09
Net Cash Flow	20.13	17.34	6.88	-7.78	11.52
Free Cash Flow	13.21	11.95	6.97	-15.43	-24.57
Free Cash Flow Growth	10.60%	71.42%	-	-	-
FCF Margin	10.21%	11.99%	8.34%	-21.42%	-36.43%
Free Cash Flow Per Share	0.15	0.15	0.09	-0.22	-0.37
Levered Free Cash Flow	10.34	13.61	-1.75	-18.82	-28.85
Unlevered Free Cash Flow	6.54	12.52	-2.41	-20.91	-28.8

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q